State Street Global Advisors - advised funds > SPDR SERIES TRUST
SPDR(R) S&P(R) Pharmaceuticals ETF
$207.94M
Avg Monthly Net Assets
$206.30M
Total Assets
$11.16M
Total Liabilities
$195.15M
Net Assets
SPDR(R) S&P(R) Pharmaceuticals ETF is an Exchange-Traded Fund in SPDR SERIES TRUST
from State Street Global Advisors - advised funds,
based in Massachusetts,
United States of America.
The fund has one share class
and monthly net assets of $207.94M.
On August 28th, 2024 it reported 45 holdings, the largest
being State Street Global Advisors (5.7%), Axsome Therapeutics Inc (4.3%) and Viatris Inc (4.1%).
Data provided by Fincoded.
Share Classes
| Name | Class/Contract ID | Exchange | Ticker | Monthly Returns (2 years) |
|---|---|---|---|---|
| SPDR(R) S&P(R) Pharmaceuticals ETF | C000033537 | ARCX | XPH |
Holdings
From latest NPORT-P, filed August 28th, 2024 for period ending June 30th, 2024.
Historic holdings data available from Fincoded.
| Name | Profile | Category | Country | Value $USD | # Shares | % of Fund |
|---|---|---|---|---|---|---|
| Amneal Pharmaceuticals Inc | Long | Equity-common | US | $2M | 326K | 1.06 |
| Amphastar Pharmaceuticals Inc | Long | Equity-common | US | $4M | 109K | 2.23 |
| ANI Pharmaceuticals Inc | Long | Equity-common | US | $3M | 45K | 1.46 |
| Arvinas Inc | Long | Equity-common | US | $7M | 247K | 3.37 |
| Axsome Therapeutics Inc | Long | Equity-common | US | $8M | 103K | 4.27 |
| Bristol-Myers Squibb Co | Long | Equity-common | US | $8M | 185K | 3.94 |
| Cassava Sciences Inc | Long | Equity-common | US | $3M | 213K | 1.35 |
| Catalent Inc | Long | Equity-common | US | $8M | 137K | 3.96 |
| Collegium Pharmaceutical Inc | Long | Equity-common | US | $4M | 119K | 1.97 |
| Corcept Therapeutics Inc | Long | Equity-common | US | $7M | 216K | 3.60 |
| Edgewise Therapeutics Inc | Long | Equity-common | US | $3M | 166K | 1.53 |
| Elanco Animal Health Inc | Long | Equity-common | US | $6M | 423K | 3.12 |
| Eli Lilly & Co | Long | Equity-common | US | $8M | 9K | 4.02 |
| Enliven Therapeutics Inc | Long | Equity-common | US | $1M | 61K | 0.73 |
| Evolus Inc | Long | Equity-common | US | $2M | 183K | 1.02 |
| EyePoint Pharmaceuticals Inc | Long | Equity-common | US | $2M | 199K | 0.89 |
| Fulcrum Therapeutics Inc | Long | Equity-common | US | $1M | 163K | 0.52 |
| Harmony Biosciences Holdings Inc | Long | Equity-common | US | $3M | 101K | 1.56 |
| Harrow Inc | Long | Equity-common | US | $2M | 73K | 0.79 |
| Innoviva Inc | Long | Equity-common | US | $2M | 147K | 1.23 |
| Intra-Cellular Therapies Inc | Long | Equity-common | US | $8M | 112K | 3.95 |
| Jazz Pharmaceuticals PLC | Long | Equity-common | IE | $7M | 67K | 3.69 |
| Johnson & Johnson | Long | Equity-common | US | $8M | 52K | 3.92 |
| Ligand Pharmaceuticals Inc | Long | Equity-common | US | $3M | 39K | 1.70 |
| Liquidia Corp | Long | Equity-common | US | $3M | 224K | 1.38 |
| Longboard Pharmaceuticals Inc | Long | Equity-common | US | $3M | 109K | 1.51 |
| Merck & Co Inc | Long | Equity-common | US | $7M | 59K | 3.73 |
| Mind Medicine MindMed Inc | Long | Equity-common | CA | $2M | 324K | 1.20 |
| Nuvation Bio Inc | Long | Equity-common | US | $883K | 302K | 0.45 |
| Ocular Therapeutix Inc | Long | Equity-common | US | $5M | 675K | 2.37 |
| Organon & Co | Long | Equity-common | US | $8M | 373K | 3.96 |
| Pacira BioSciences Inc | Long | Equity-common | US | $4M | 140K | 2.06 |
| Perrigo Co PLC | Long | Equity-common | IE | $7M | 284K | 3.73 |
| Pfizer Inc | Long | Equity-common | US | $8M | 277K | 3.97 |
| Pliant Therapeutics Inc | Long | Equity-common | US | $1M | 111K | 0.61 |
| Prestige Consumer Healthcare Inc | Long | Equity-common | US | $5M | 69K | 2.44 |
| Royalty Pharma PLC | Long | Equity-common | GB | $7M | 283K | 3.82 |
| State Street Institutional Liquid Reserves Fund (State Street Global Advisors) | Long | Short-term investment vehicle | US | $166K | 166K | 0.08 |
| State Street Navigator Securities Lending Portfolio II (State Street Global Advisors) | Long | Short-term investment vehicle | US | $11M | 11M | 5.69 |
| Supernus Pharmaceuticals Inc | Long | Equity-common | US | $4M | 144K | 1.97 |
| Tarsus Pharmaceuticals Inc | Long | Equity-common | US | $4M | 141K | 1.97 |
| Viatris Inc | Long | Equity-common | US | $8M | 749K | 4.08 |
| WaVe Life Sciences Ltd | Long | Equity-common | SG | $755K | 151K | 0.39 |
| Xeris Biopharma Holdings Inc | Long | Equity-common | US | $830K | 369K | 0.43 |
| Zoetis Inc | Long | Equity-common | US | $8M | 45K | 3.97 |
Address
SPDR SERIES TRUST
One Iron Street
Boston
Massachusetts
02210
United States of America
Websites
Directors
Sandra G. Sponem
Dwight D. Churchill
Gunjan Chauhan
Carolyn M. Clancy
Carl G. Verboncoeur
James E. Ross
Clare S. Richer
Kristi L. Rowsell
Transfer Agents
State Street Bank and Trust Company
Pricing Services
Bloomberg L.P.
London Stock Exchange Group PLC
S&P Global Inc.
PricingDirect Inc.
ICE Data Services, Inc.
Custodians
State Street Bank and Trust Company
Shareholder Servicing Agents
State Street Bank and Trust Company
Admins
State Street Bank and Trust Company
SSGA Funds Management, Inc.
Brokers
N/A